Northwest Biotherapeutics Stock Probability of Future OTC Stock Price Finishing Over 0.27
| NWBO Stock | USD 0.27 0.01 3.85% |
Northwest |
Northwest Biotherapeutics Target Price Odds to finish over 0.27
The tendency of Northwest OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.27 | 90 days | 0.27 | about 82.95 |
Based on a normal probability distribution, the odds of Northwest Biotherapeutics to move above the current price in 90 days from now is about 82.95 (This Northwest Biotherapeutics probability density function shows the probability of Northwest OTC Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the otc stock has the beta coefficient of 1.4 . This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Northwest Biotherapeutics will likely underperform. Additionally Northwest Biotherapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Northwest Biotherapeutics Price Density |
| Price |
Predictive Modules for Northwest Biotherapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Northwest Biotherapeutics. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Northwest Biotherapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Northwest Biotherapeutics is not an exception. The market had few large corrections towards the Northwest Biotherapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Northwest Biotherapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Northwest Biotherapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.34 | |
β | Beta against Dow Jones | 1.40 | |
σ | Overall volatility | 0.02 | |
Ir | Information ratio | -0.08 |
Northwest Biotherapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Northwest Biotherapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Northwest Biotherapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Northwest Biotherapeutics generated a negative expected return over the last 90 days | |
| Northwest Biotherapeutics has some characteristics of a very speculative penny stock | |
| Northwest Biotherapeutics has high historical volatility and very poor performance | |
| Northwest Biotherapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Northwest Biotherapeutics currently holds 25.16 M in liabilities. Northwest Biotherapeutics has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Northwest Biotherapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Northwest Biotherapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Northwest Biotherapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Northwest to invest in growth at high rates of return. When we think about Northwest Biotherapeutics' use of debt, we should always consider it together with cash and equity. | |
| Northwest Biotherapeutics currently holds about 9.43 M in cash with (38.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. |
Northwest Biotherapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Northwest OTC Stock often depends not only on the future outlook of the current and potential Northwest Biotherapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Northwest Biotherapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 948.4 M | |
| Cash And Short Term Investments | 15.2 M |
Northwest Biotherapeutics Technical Analysis
Northwest Biotherapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Northwest OTC Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Northwest Biotherapeutics. In general, you should focus on analyzing Northwest OTC Stock price patterns and their correlations with different microeconomic environments and drivers.
Northwest Biotherapeutics Predictive Forecast Models
Northwest Biotherapeutics' time-series forecasting models is one of many Northwest Biotherapeutics' otc stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Northwest Biotherapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the otc stock market movement and maximize returns from investment trading.
Things to note about Northwest Biotherapeutics
Checking the ongoing alerts about Northwest Biotherapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Northwest Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Northwest Biotherapeutics generated a negative expected return over the last 90 days | |
| Northwest Biotherapeutics has some characteristics of a very speculative penny stock | |
| Northwest Biotherapeutics has high historical volatility and very poor performance | |
| Northwest Biotherapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Northwest Biotherapeutics currently holds 25.16 M in liabilities. Northwest Biotherapeutics has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Northwest Biotherapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Northwest Biotherapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Northwest Biotherapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Northwest to invest in growth at high rates of return. When we think about Northwest Biotherapeutics' use of debt, we should always consider it together with cash and equity. | |
| Northwest Biotherapeutics currently holds about 9.43 M in cash with (38.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. |
Other Information on Investing in Northwest OTC Stock
Northwest Biotherapeutics financial ratios help investors to determine whether Northwest OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Northwest with respect to the benefits of owning Northwest Biotherapeutics security.